Development of a new workflow for multiple attribute methodology (MAM) of an





Armelle Martelet¹, Valérie Garrigue¹, Hélène Le Borgne¹, Zoe Zhang², Bruno Genet¹, <u>Kerstin Pohl²</u> ¹Sanofi, France; ²SCIEX, USA

SANOFI

INTRODUCTION

- There are a variety of post-translational modifications (PTMs) known to occur in monoclonal antibody and ADC biotherapeutics during the manufacturing, formulation, and storage process
- Monitoring these quality attributes is of major interest because of the potential impact on a product's safety and efficacy
- Peptide mapping analysis using liquid chromatography mass spectrometry (LC-MS) based detection is commonly used for the identification and the relative quantification of attributes such as e.g. oxidation and deamidation
- However, establishing a workflow for streamlined data analysis can be challenging for stability and especially forced degradation studies with increasing numbers of samples.

MATERIALS AND METHODS

For forced degradation assessment ADC samples underwent thermal, mechanical and chemical stresses. All samples, including controls, were reduced, alkylated and enzymatically digested. Obtained peptides were separated on a reversed-phase C18 column using a high-flow LC setup (ExionLC™ System). MS detection was carried out on a quadrupole-timeof-flight instrument (SCIEX X500B QTOF System) using data-dependent acquisition. Subsequent data analysis was performed using SCIEX OS Software 1.7 in a new streamlined way combining a high level of automation for calculations, ease of review, and verification of the results.





Figure 1. Summary of quality attributes used for tracking purposes. Oxidation, deamidation and isoaspartate formation were defined to be monitored as part of the degradation assessment. Up to four charge states from each peptides were considered in quantification.






Figure 3. User-defined calculations for automatic % calculation for each modification. An automatic calculation of modification percentages based on extracted ion chromatograms (XIC) areas of modified peptides against all other forms of the same peptide was set up. Up to four charge states were summed to achieve a precise calculation (A), followed by a percentage calculation (B).




Figure 4. Flagging rules for different parameters within MAM assay. To achieve an accurate identification and high throughput, attribute pass/fail criteria were defined for retention time (A), mass accuracy (B) and modification percentage (C). Any attribute which fails the set criteria will be flagged in the assay table by a color scheme, facilitating data review.






Figure 5. Results of the final MAM assay for the ADC stress study. Summary of all attributes in a table format (A). For each attribute XIC (B), underlying MS (C) and MS/MS (D) information is available. An overlay of the MS information with the theoretical isotope patterns provides full confidence in the assignment (gray pattern in C). Attributes failing the set criteria (red highlights) were interrogated further.




Figure 6. Oxidation change on the peptide DTLMISR. Metric plot of the modification percentage change across stressed samples showing increasing levels of oxidation with increasing stress time. The metric plot can be directly generated inside the results table as a visualization tool for easy and quick comparison of samples.

CONCLUSIONS

- The established MAM assay represents a comprehensive solution for monitoring product quality attributes (PQA)
- A very flexible and automatic calculation of the percentage of modification including visual tools (metric plot, flagging of out-ofrange parameters) speeds up the assessment of PQAs
- The streamlined workflow is compliant-ready, thus can be transferred to departments with further regulatory requirements

TRADEMARKS/LICENSING

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.

© 2020 DH Tech. Dev. Pte. Ltd. RUO-MKT-10-11573-B. AB SCIEX™ is being used under license